Condition
Type 2 Diabetes Mellitus With Circulatory Complciation
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04232774Not ApplicableCompletedPrimary
Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
NCT04390711CompletedPrimary
Association of Carbamylated HDL and CAD in T2DM Patients
NCT04141241Phase 2CompletedPrimary
Phase 2a Study to Evaluate the Safety and Efficacy of PH100 Tablet in T2DM Patients With Recent Cardiovascular
Showing all 3 trials